| 000 | 01217 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250517143002.0 | ||
| 264 | 0 | _c20190111 | |
| 008 | 201901s 0 0 eng d | ||
| 022 | _a1878-7436 | ||
| 024 | 7 |
_a10.1016/j.jash.2016.12.008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLevy, Daniel | |
| 245 | 0 | 0 |
_aFrom the Editor. _h[electronic resource] |
| 260 |
_bJournal of the American Society of Hypertension : JASH _c01 2017 |
||
| 300 |
_a1-2 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 650 | 0 | 4 |
_aAntihypertensive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCholesterol, LDL _xblood |
| 650 | 0 | 4 | _aCongresses as Topic |
| 650 | 0 | 4 |
_aCoronary Disease _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aHypertension _xdrug therapy |
| 650 | 0 | 4 |
_aNutrition Surveys _xstatistics & numerical data |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 |
_aRisk Assessment _xstandards |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 773 | 0 |
_tJournal of the American Society of Hypertension : JASH _gvol. 11 _gno. 1 _gp. 1-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jash.2016.12.008 _zAvailable from publisher's website |
| 999 |
_c26959442 _d26959442 |
||